Tamoxifen therapy for encapsulating peritoneal sclerosis: Mechanism of action and update on clinical experiences

Peritoneal Dialysis International

Volumn 29, Issue 3, 2009, Pages 252-255

  Guest, Steven ^a,b,c  

^a KAISER PERMANENTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AZATHIOPRINE; ESTROGEN; GLUCOCORTICOID; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; LACTIC ACID; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

BREAST CANCER; CELL MIGRATION; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE COMPARISON; DRUG TOLERABILITY; ENCAPSULATING PERITONEAL SCLEROSIS; FATIGUE; FIBROBLAST; HOT FLUSH; HUMAN; IMMUNOCOMPROMISED PATIENT; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL MEMBRANE; PERITONEUM; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SCLEROSIS; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 67649378656     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080902900304     Document Type: Review

References (31)

1. Nakamoto H. Encapsulating peritoneal sclerosis - a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005; 25(Suppl 4):S30-8.
2. De Freitas D, Jordaan A, Williams R, Alderdice J, Curwell J, Hurst H, et al. Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. Perit Dial Int 2008; 28:271-6.
3. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44:729-37.
4. Korte M, Yo M, Betjes M, Fieren M, Saase J, Boer W, et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant 2007; 22:2412-14.
5. Moustafellos P, Hadjianastassiou V, Roy D, Velzeboer N, Maniakyn N, Vaidya A, et al. Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation. Transplant Proc 2006; 38:2913-14.
6. Ahmad M, Shah H, Pliakogiannis T, Oreopoulos DG. Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions. Int Urol Nephrol 2007; 39:299-312.
7. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan J, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348:403-13.
8. Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B, et al. Tacrolimus enhances transforming growth factor β1 expression and promotes tumor progression. Transplantation 2003; 76:597-602.
9. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S. Expression of TGF-β and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002; 62:2257-63.
10. Kawanishi H, Moriishi M, Ide K, Dohi K. Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis. Perit Dial Int 2008; 28(Suppl 3): S205-10.
11. Lafrance J, Letourneau I, Ouimet D, Bonnardeaux A, Leblanc M, Mathieu N, et al. Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis 2008; 51:e7-10.
12. Van Bommel E, Hendriksz T, Huiskes A, Zeegers A. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 2006; 144:101-6.
13. Turner MW, Holleman JH. Successful therapy of sclerosing peritonitis. Semin Dial 1992; 5:316.
14. Margetts PJ, Bonniaud P, Liu L, Hoff C, Holmes C, West-Mays J, et al. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005; 16:425-36.
15. De Vriese A, Tilton R, Mortier S, Lameire N. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006; 21:2549-55.
16. Payne WG, Ko F, Anspaugh S, Wheeler C, Wright T, Robson M. Down-regulating causes of fibrosis with tamoxifen: a possible cellular/ molecular approach to treat rhinophyma. Ann Plast Surg 2006; 56:301-5.
17. Eltoum M, Wright S, Atchley J, Mason J. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 2006; 26:203-6.
18. Summers AM, Clancy MJ, Syed F, Harwood N, Brenchley P, Augustine T, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005; 68: 2381-8.
19. Del Peso G, Bajo A, Gil F, Aguilera A, Ros S, Costero O, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003; 19:32-5.
20. Selgas R, Aguilera A, Bajo A, Loureiro J, Del Peso G, Aroeira L, et al. Effects of tamoxifen on epithelial-to-mesenchymal transition (EMT), fibrosis and angiogenesis of mesothelial cells [Abstract]. J Am Soc Nephrol 2006; 17:758A.
21. Allaria P, Giangrande A, Gandini E, Pisoni I. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? J Nephrol 1999; 12:395-7.
22. Pollock C. Bloody ascites in a patient after transfer from peritoneal dialysis to hemodialysis. Semin Dial 2003; 16: 406-10.
23. Evrenkaya TR, Atasoyu EM, Unver S, Basekim C, Baloglu H, Tulbek MY. Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2004; 19:2423-4.
24. Korzets A, Ori Y, Zevin D, Chagnac A, Herman M, Rozen-Zvi B, et al. A worrying thought - could there be a connection between encapsulating peritoneal sclerosis, tamoxifen and calciphylaxis? Nephrol Dial Transplant 2006; 21:2975-8.
25. Mesquita M, Guillaume MP, Dratwa M. First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis. Clin Drug Invest 2007; 27:727-9.
26. Thirunavukarasu T, Saxena R, Anijeet H, Pai P, Wong CF. Encapsulating peritoneal sclerosis presenting with recurrent ascites and tamoxifen: case reports and review of the literature. Ren Fail 2007; 29:775-6.
27. Dogan E, Ucmak H, Sayarlioglu H, Sahin M, Ucar M, Gunduz M. Sclerosing encapsulating peritonitis in an anti-HCV-positive patient on chronic ambulatory peritoneal dialysis. Ren Fail 2007; 29:777-8.
28. Gupta S, Woodrow G. Successful treatment of fulminant encapsulating peritoneal sclerosis following fungal peritonitis with tamoxifen. Clin Nephrol 2007; 68:125-9.
29. Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, Roberts JD, et al. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol 2003; 120: 109-16.
30. Cosman F, Baz-Hecht M, Cushman M, Vardy MD, Cruz JD, Nieves JW, et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res 2005;116:1-13.
31. Dobrydneva Y, Weatherman R, Trebley J, Morrell M, Fitzgerald M, Fichandler C, et al. Tamoxifen stimulates calcium entry into human platelets. J Cardiovasc Pharmacol 2007; 50:380-90.